Pfizer awards manufacturing contract for heartburn treatment to Catalent

Published: 8-Dec-2015
Manufacturing

Catalent will formulate and manufacture Nexium into enteric coated, delayed release pellets using fluid-bed technology


Catalent Pharma Solutions has entered into an exclusive long-term supply agreement to produce Pfizer’s leading over-the-counter (OTC) heartburn treatment, Nexium 24HR (esomeprazole), also marketed as Nexium Control outside the US.

Under the agreement, Catalent’s Winchester, Kentucky, US facility will formulate and manufacture the 20mg Proton Pump Inhibitor drug into enteric coated, delayed release pellets using fluid bed technology. The firm will also encapsulate these pellets into two-piece, hard-shell capsules, where the company has invested in the capsule banding technology required for OTC products.

Pfizer secured the exclusive global rights to market Nexium for the approved OTC indications from AstraZeneca in 2012. Nexium 24HR is now the leading OTC heartburn brand in the US. AstraZeneca continues to manufacture and sell the prescription product.

'Nexium is one of the leading global OTC medicines and its manufacture is well suited to our recently expanded Winchester facility, where we have both the capacity and flexibility to accommodate programmes of this scale,' said Barry Littlejohns, Catalent’s President of Advanced Delivery Technologies.

  • Companies:
  • Pfizer
  • Catalent
See more

You may also like

Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Read more
Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Manufacturing

Catalent adds cryogenic capabilities to support gene development

The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials
Manufacturing

Catalent begins $20 million construction project

The project creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line
Manufacturing

Catalent and Bhami announce licensing agreement

Catalent will be authorised to collaborate with its customers to evaluate BRL’s formulation technology
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Manufacturing

Catalent completes $2.2 million expansion to clinical supply facility

The site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services
Subscribe now